长江商报消息 ●长江商报记者 江楚雅 利德曼计划通过并购寻求新的增长曲线，推动企业转型。 近日，利德曼（300289.SZ）发布公告称，计划以17.33亿元现金收购北京先声祥瑞生物制品股份有限公 司（下称"先声祥瑞"）70%股份。 本次交易完成后，先声祥瑞将成为利德曼控股子公司，利德曼也将借此切入生物制品领域，构建"生物 制品+体外诊断"双主业模式。 业内认为，通过本次交易，上市公司的业绩将得到提升，财务状况将得到进一步改善，有利于维护上市 公司股东的利益。 标的近年业绩表现稳定 对应高溢价，交易对手方作出了明确的业绩承诺。先声祥瑞2025年、2026年、2027年扣非归母净利润分 别不低于1.66亿元（若剔除2025年mRNA平台费用1035.57万元，则为1.76亿元）、1.86亿元、2.08亿 元，三年累计扣非归母净利润不低于5.58亿元。 先声祥瑞的业务布局是此次收购的核心吸引力之一。作为拥有疫苗生产许可证的企业，其管线覆盖尚未 满足临床需求的人用创新疫苗，其中应用于脑膜炎领域的Xs03项目已提交pre-IND，另有多个创新项目 处于临床前阶段。此外，先声祥瑞在体外诊断试剂的研发、生产和销售领域也具备 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2][19]. Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 3.29%, outperforming the Wind All A index (-0.47%) and the CSI 300 index (-1.08%) during the week of November 10-14, 2025 [3][8]. - Local governments are actively implementing policies to support innovative drug development, with Chongqing aiming to approve 1-3 new drugs annually by 2027 [3][13]. - Flu activity is on the rise, with the percentage of flu-like illness cases reported in southern provinces reaching 5.5%, higher than the previous week and the same period in 2022 and 2024 [3][13]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 3.29%, with all sub-sectors recovering. The leading sub-sectors included pharmaceutical distribution (5.92%), in vitro diagnostics (5.91%), and raw materials (5.09%) [3][8]. - Notable stock performances included Jindike (61.6%), Renmin Tongtai (61.1%), and Chengda Pharmaceutical (58.3%) with significant gains, while *ST Changyao (-33.6%) and Zhend Medical (-11.3%) faced substantial declines [3][11]. Industry News and Key Company Announcements - On November 14, Chongqing's government announced comprehensive support measures for innovative drug development, including funding for research and expedited ethical review processes [3][13]. - Merck announced a $9.2 billion acquisition of Cidara Therapeutics, expected to close in Q1 2026 [3][13]. - Adicon acquired Crown Bioscience for $204 million, aiming to enhance its integrated service platform [3][13]. - Laika Pharmaceuticals entered an exclusive licensing agreement with Qilu Pharmaceutical for LAE002, with potential payments totaling RMB 25.75 billion [3][14]. - Lyell Immunopharma announced a global licensing agreement for LYL273, with significant milestone payments and royalties [3][15]. - MeiraGTx Holdings entered a strategic collaboration with Eli Lilly for gene therapy projects, with upfront and milestone payments exceeding $400 million [3][15].

Core Viewpoint - The stock price of Saikexide has shown fluctuations, with a year-to-date increase of 14.13% but a recent decline of 2.01% in the last trading session, indicating potential volatility in the market [1][2]. Company Overview - Saikexide Technology Co., Ltd. is located in Daxing District, Beijing, and was established on May 28, 2003. The company was listed on August 6, 2020, and primarily engages in the research, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [2]. - The revenue composition of Saikexide includes reagents (53.71%), instruments (25.40%), consumables (20.58%), and other (0.31%) [2]. Financial Performance - For the period from January to September 2025, Saikexide reported a revenue of 196 million yuan, representing a year-on-year decrease of 13.62%. The net profit attributable to the parent company was approximately 64.56 million yuan, down 22.83% year-on-year [2]. - As of September 30, the number of shareholders increased by 3.44% to 7,012, while the average circulating shares per person decreased by 3.32% to 15,137 shares [2]. Market Activity - On November 17, Saikexide's stock price fell by 2.01%, trading at 27.24 yuan per share with a total market capitalization of 2.891 billion yuan. The trading volume was 8.4171 million yuan, with a turnover rate of 0.29% [1]. - The net outflow of main funds was 381,800 yuan, with large single purchases amounting to 224,600 yuan (2.67% of total) and sales of 606,400 yuan (7.20% of total) [1]. Dividend Information - Since its A-share listing, Saikexide has distributed a total of 136 million yuan in dividends, with 83.14 million yuan distributed over the past three years [3].

Core Insights - Oriental Bio has recently announced the acquisition of multiple medical device registration certificates, including 10 respiratory test kits, which are significant for both domestic and EU markets [1][2] Group 1: Product Registrations - The company obtained the "Mycoplasma pneumoniae antigen detection kit (latex method)" registration certificate in China, valid until November 3, 2030 [1] - Hangzhou Laihe, a subsidiary, received 9 EU IVDR certifications for various combined respiratory tests, covering major pathogens such as COVID-19, influenza A and B, and respiratory syncytial virus [1] Group 2: Market Strategy - Oriental Bio has established itself as a leader in the IVD industry for infectious disease testing, with over ten EU CE IVDR registrations and multiple FDA and NMPA registrations, making it one of the companies with the most global certifications in respiratory testing [2] - The company employs a dual strategy of "professional version + self-test version," significantly expanding its market coverage [2] Group 3: Market Impact - The acquisition of these registrations is expected to enhance the company's product offerings in respiratory testing, aiding market expansion, although the actual sales performance will depend on product competitiveness and market sales capabilities [1]

Core Insights - The article highlights the rapid growth and strategic advancements of Dana Biotech, a biotechnology company from Tianjin Eco-City, specializing in early diagnosis of invasive fungal diseases. The company has effectively utilized the North Exchange's direct connection mechanism for efficient financing and has developed a clear strategic plan for future technologies like "5G + joint detection" [1]. Group 1: Capital Market Adaptation - Dana Biotech is the first company in the in vitro diagnostic industry to be listed on the North Exchange, which aligns well with its current development stage and needs [2]. - The direct connection mechanism introduced by the North Exchange in December 2022 has significantly improved capital matching efficiency, allowing Dana Biotech to submit its listing application just two months after its new third board listing [2][3]. - The North Exchange's innovative system has provided valuable development time for innovative enterprises, which is crucial for their growth [3]. Group 2: Supply Chain and Competition - The company faces a "bottleneck" risk due to the scarcity of key raw materials, specifically the blood cells from horseshoe crabs, which are now a protected species. However, Dana Biotech has secured a five-year supply of inventory and has imported 60 kilograms of raw material from Vietnam [3][4]. - Dana Biotech has established six core technology platforms covering various fields, with 91 patents expected by June 2025, including 49 invention patents [3]. Group 3: Market Position and Growth - Dana Biotech has achieved a domestic market share of 30% in the invasive fungal disease detection sector, surpassing competitors like US-based companies [4]. - The company is expanding its product line to include respiratory pathogen detection, with a new product line currently in clinical trials [5]. - The in vitro diagnostic market in China is projected to grow from 71.3 billion yuan in 2018 to 415.2 billion yuan by 2030, with the invasive fungal disease diagnostic segment experiencing a compound annual growth rate of 23.5% [5]. Group 4: Future Plans and Innovations - Dana Biotech plans to invest 302 million yuan in building a headquarters in Tianjin Eco-City, aiming for a production capacity of 65.06 million tests [5]. - The company intends to leverage capital market opportunities for mergers and acquisitions to expand its business boundaries and create a comprehensive diagnostic solution for pathogenic microorganisms [5].

Core Insights - The company, Maike Biological, has focused on the research, production, sales, and related services of in vitro diagnostic products for over 30 years, establishing a comprehensive capability in the industry [1] - The company has developed a full industry chain from biological raw materials to specialized services and is now entering a phase of building intelligent laboratories with automated and smart products [1] - The application of artificial intelligence (AI) is concentrated in the field of in vitro diagnostics, with achievements in AI-assisted detection and image recognition [1] - AI and big data models are being applied to projects involving urine, blood cells, and pathology [1] - The company's intelligent laboratory solutions aim to achieve full-process intelligent management from sample collection, transmission, processing to detection results [1] - The company is also exploring the application of AI technology in broader medical fields [1]

智通财经记者 | 李科文 智通财经编辑 | 谢欣 11月13日晚间，国内第三大独立医学实验室（ICL）服务商艾迪康公告，公司全资子公司拟从JSR生命 科学收购冠科生物（Crown Bioscience International）。本次交易基础对价为2.04亿美元（折合人民币 14.47亿元），最终金额将根据交割后常规调整情况作相应调整。交易预计将于2026年年中完成。 这也意味着，艾迪康将跨界合同研究代工（CRO）行业。需要注意的是，本次交易完成后，冠科生物 仍保持独立运营。其中，异种移植（PDX）模型库、肿瘤类器官平台、免疫肿瘤学检测及生物信息学解 决方案等资产将整合到艾迪康；全球生物样本业务（总部位于德国汉堡，在美国马里兰州弗雷德里克设 有研发中心）资产则保留在JSR生命科学。 就在同日，同在体外诊断行业的利德曼也公告了其跨界生物制品行业的新进展。利德曼拟以支付现金的 方式购买北京先声祥瑞生物制品股份有限公司（简称"先声祥瑞"）70%的股份，交易价格为17.33亿元。 11月14日，智通财经联系艾迪康，截至发稿未获回复。同日，智通财经联系冠科生物，截至发稿未获回 复。同日，智通财经也联系利德曼，截至发稿 ...

Core Viewpoint - Lidman plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, aiming to enter the high-barrier bioproducts industry and transform its business model to include both bioproducts and in vitro diagnostics [1][2] Group 1: Acquisition Details - The acquisition involves cash payment to three entities: Shanghai Baijiahui Investment Management Co., Nanjing Baijiarui Enterprise Management Consulting Partnership, and Hainan Xiansheng Baijiahui Technology Development Co. [1] - After the transaction, Lidman will hold 70% of Xiansheng Xiangrui, consolidating it into its financial statements [1] Group 2: Strategic Rationale - The acquisition allows Lidman to quickly penetrate the bioproducts market, which has high barriers to entry and significant growth potential [2] - Xiansheng Xiangrui is recognized as a "little giant" enterprise in Beijing and holds a vaccine production license, with unique technologies in TB-PPD and BCG-PPD preparation [2] Group 3: Financial Performance - Xiansheng Xiangrui's projected revenues for 2023, 2024, and the first seven months of 2025 are 653 million yuan, 582 million yuan, and 228 million yuan, respectively, with net profits of 210 million yuan, 180 million yuan, and 59.68 million yuan [2] - Lidman expects the acquisition to turn its consolidated net profit positive [2] Group 4: Lidman's Current Situation - Lidman, established in 1997, focuses on in vitro diagnostic reagents and instruments but has faced revenue fluctuations due to increased competition and centralized procurement [3] - For 2024, Lidman's revenue is projected at 370 million yuan, with a net loss of 75.1 million yuan; the first three quarters of this year showed a 10.49% revenue decline [3] - As of the end of Q3, Lidman had cash reserves of 618 million yuan, and the acquisition will result in approximately 1.019 billion yuan of goodwill on its balance sheet [3]

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

Group 1 - Duopule plans to reduce its shareholding by no more than 1%, amounting to a maximum of 619,000 shares [1] - Lideman intends to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, focusing on tuberculosis screening and diagnosis [2] - Huahuan Group is planning a change in control, leading to a temporary suspension of its stock [3] Group 2 - Dongbai Group clarifies it does not engage in duty-free business, maintaining normal operations [4][5] - Changsheng Bearing's actual controller plans to reduce holdings by up to 1.99%, equating to 5.94 million shares [6][7] - Jidian plans to invest 5.698 billion yuan in the Baicheng Phase II coal power project, a key initiative under the national "14th Five-Year Plan" [9][10] Group 3 - Baoneng New Energy reports completion of land-based works for the expansion of the Lufeng Qiaohai Bay Power Plant [11][12] - Changshu Bank proposes to appoint Lu Dingchang as the new president and chief compliance officer [13][14] - Kangqiang Electronics plans to reduce its shareholding by no more than 1%, totaling up to 3.7526 million shares [14] Group 4 - Jilin Chemical Fiber intends to reduce its holdings by up to 2%, equating to 49.1774 million shares [15][16] - CanSino's inhaled tuberculosis vaccine has commenced Phase I clinical trials in Indonesia [17][18] - ST Dongyi's stock has been suspended for review due to significant price fluctuations [19] Group 5 - ST Yatai plans to reduce its holdings by up to 1.98%, totaling 6.4 million shares [20] - Huaren Pharmaceutical intends to reduce its holdings by up to 3%, equating to 35.4663 million shares [21] - Jianglong Shipbuilding's controlling shareholder plans to reduce holdings by up to 2%, amounting to 7.5534 million shares [22] Group 6 - Borui Pharmaceutical's BGM1812 injection has received approval for clinical trials targeting overweight or obesity [23][24] - ST Zhongzhu announces the transfer of 10.38% of its shares, totaling approximately 403 million yuan [25][26] - Shenzhou Digital plans to establish an employee stock ownership plan with a maximum fundraising of 360 million yuan [27][28] Group 7 - Kaichuang Electric plans to establish a joint research center with Tsinghua University, focusing on embodied intelligence [29] - Daming City intends to acquire 19.43% of Baicaibang for 694 million yuan, specializing in communication solutions [29]